Market Place
Sourcing Support
Tremfya is 1st IL-23 Inhibitor with Subcutaneous in Crohn`s Disease
28 Oct 2024 //
PR NEWSWIRE
Positive results for J&J’s Tremfya in plaque psoriasis
26 Oct 2024 //
PRESS RELEASE
J&J’s Tremfya May Set New Standard In Crohn’s Disease
21 Oct 2024 //
FINANCIALXPRESS
New J&J Tremfya ad puts inclusive twist on psoriasis marketing
16 Oct 2024 //
FIERCE PHARMA
TREMFYA Shows Impressive Results In Crohn`s And Ulcerative Colitis
10 Oct 2024 //
PR NEWSWIRE
US FDA expands J&J`s psoriasis drug for inflammatory bowel disease
12 Sep 2024 //
REUTERS
Janssen Biotech`s Biologic Tremfya (Guselkumab) Receives Approval in US
11 Sep 2024 //
FDA
J&J nixes Tremfya trial in giant cell arteritis
26 Jun 2024 //
FIERCE PHARMA
TREMFYA Studies Show Potential For SC And IV Induction As IL-23 Inhibitor
20 Jun 2024 //
PR NEWSWIRE
Innovent looks to Chinese regulators after ph. 3 psoriasis win
28 May 2024 //
FIERCE BIOTECH
J&J’s Tremfya trumps placebo, Stelara in Phase III Crohn`s trial
22 May 2024 //
PRESS RELEASE
TREMFYA Superiority Vs STELARA Shown In Crohn`s Phase 3
21 May 2024 //
PR NEWSWIRE
TREMFYA UC Maintenance Study Meets Primary & Major Secondary Endpoints
20 May 2024 //
PR NEWSWIRE
J&J readies Tremfya for IBD showdown with AbbVie, Lilly
20 May 2024 //
FIERCE PHARMA
J&J Seeks EMA Approval For Tremfya In UC, Crohn`s Disease
01 May 2024 //
PR NEWSWIRE
J&J submits supplemental BLA to U.S. FDA seeking approval of TREMFYA
11 Mar 2024 //
PR NEWSWIRE
Data Show TREMFYA Was Associated With Improvements in Psoriatic Arthritis
08 Nov 2023 //
PR NEWSWIRE
J&J’s first psoriasis study opens door to marketing communications
26 Oct 2023 //
ENDPTS
Phase 3 TREMFYA Results in Ulcerative Colitis Show a 77% Overall Response Rate
23 Oct 2023 //
PR NEWSWIRE
Janssen Announces TREMFYA® (guselkumab) Demonstrates Significant Skin Clearance
20 Oct 2023 //
PR NEWSWIRE
TREMFYA Maintains Key Efficacy Endpoints Through Three Years for Adults
16 Oct 2023 //
PR NEWSWIRE
Janssen Highlights Latest Research for TREMFYA® (guselkumab)
09 Oct 2023 //
PR NEWSWIRE
Janssen Tremfya excels as psoriasis treatment, outshining IL-17s
01 Jun 2023 //
INDIAN PHARMA POST
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
10 May 2023 //
CLINICAL TRIALS ARENA
PIII TREMFYA Data in Inflammatory Bowel Disease Show Positive Induction Results
09 May 2023 //
PRESS RELEASE
First Phase 3 TREMFYA® Data in Inflammatory Bowel Disease +Ve Results
09 May 2023 //
PR NEWSWIRE
TREMFYA Demonstrates a Differentiated Binding Mechanism from Risankizumab
03 Mar 2023 //
PR NEWSWIRE
New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis
10 Nov 2022 //
PRNEWSWIRE
TREMFYA Data Show an Clinical Response Rate of 80% in a Phase 2b Study
24 Oct 2022 //
PRNEWSWIRE
J&J uncorks new Tremfya data in ulcerative colitis
24 Oct 2022 //
ENDPTS
J&J Ulcerative Colitis Clinical Trial Produces High Rate of Remission
13 Oct 2022 //
PHARMANEWSINTEL
Study of Guselkumab & Golimumab Therapy Show Higher Rates of Clinical Remission
10 Oct 2022 //
PRNEWSWIRE
J&J`s Janssen unveils PhII ulcerative colitis data for Tremfya combo
10 Oct 2022 //
ENDPTS
Janssen confirms psoriasis treatment Tremfya binds to CD64+ cells and IL-23
20 Jun 2022 //
KOREABIOMED
New Data Show Patients Treated with TREMFYA Achieve Durable Efficacy
01 Jun 2022 //
PRNEWSWIRE
Janssen Presents Study Results Showing Results of TREMFY and STELARA
24 May 2022 //
PRNEWSWIRE
Plaque Psoriasis Treated with First-in-Class TREMFYA
25 Mar 2022 //
PRNEWSWIRE
Results of Novel Study Show Adults with UC Achieved Higher Response Rates
19 Feb 2022 //
PRNEWSWIRE
J&J makes its case for Tremfya in two IBD indications
18 Feb 2022 //
FIERCEPHARMA
Tremfya ranks highest for skin clearance in psoriatic arthritis patients
26 Jan 2022 //
EUROPEANPHARMACEUTICALREVIEW
Crohn’s patients see 65% remission in clinical trial
18 Nov 2021 //
PHARMAFILE
Crohn’s patients achieve 65 percent clinical remission with Tremfya
17 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
New Phase 3 First-in-Class TREMFYA Data Show Durability of Joint Efficacy in PsA
01 Nov 2021 //
PRNEWSWIRE
J&J`s Tremfya scores 5-year psoriasis win in AAD data dump; Roche
23 Apr 2021 //
ENDPTS
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab)
16 Mar 2021 //
PRNEWSWIRE
J&J touts two-year data for Tremfya in psoriatic arthritis
16 Mar 2021 //
FIERCEPHARMA
LEO Pharma initiates head-to-head study to evaluate brodalumab
13 Jan 2021 //
PRESS RELEASE
LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab
13 Jan 2021 //
BUSINESSWIRE
European Commission Approves Janssen’s TREMFYA®? (guselkumab)
25 Nov 2020 //
BUSINESSWIRE
European Commission Approves Janssen’s TREMFYA®? (guselkumab)
24 Nov 2020 //
BUSINESSWIRE
New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab
15 Oct 2020 //
PRNEWSWIRE
Janssen’s phase 3 VOYAGE 1 study of Tremfya showed high rates of skin clearance
15 Oct 2020 //
PHARMABIZ
TREMFYA® (guselkumab) Induces Clinical and Endoscopic Improvements
12 Oct 2020 //
BIOSPACE
Health Canada Approves TREMFYA®* (guselkumab injection)
10 Sep 2020 //
NEWSWIRE
Janssen Biotech`s Tremfya (Guselkumab ) Receives Supplemental Approval in US
16 Jul 2020 //
FDA
J&J`s Tremfya grabs psoriatic arthritis nod
14 Jul 2020 //
FIERCE PHARMA
J&J nabs new OK for IL-23 drug Tremfya; Merck KGaA spinout ups Series A
14 Jul 2020 //
ENDPTS
Tremfya`s skin clearance benefit lasts up to 4Y plaque psoriasis, Janssen says
15 Jun 2020 //
PHARMAFILE
